Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-22-000052
Filing Date
2022-05-05
Accepted
2022-05-05 16:20:37
Documents
6
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 2022 FIRST QUARTER 6-K q12022form6-k.htm 6-K 23047
2 EX-99.1 2022 FIRST QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsmarch312022.htm EX-99.1 310883
3 EX-99.2 2022 FIRST QUARTER MD&A ex992-q12022mda.htm EX-99.2 187850
4 EX-99.3 Q1 2022 CERTIFICATION CEO ex993-q12022certificationx.htm EX-99.3 14747
5 EX-99.4 Q1 2022 CERTIFICATION CFO ex994-q12022certificationx.htm EX-99.4 14644
6 oncolyticslogotaglineblueaa.jpg GRAPHIC 355294
  Complete submission text file 0001129928-22-000052.txt   991588
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 22896631
SIC: 2834 Pharmaceutical Preparations